Burkina Faso

To lower the risk of cancers associated with human papillomavirus (HPV), Burkina Faso introduced HPV vaccination into its routine immunization program. The campaign provided nine-year-old girls with vaccine access, in accordance with the current immunization schedule. The initiative was launched off in April 2022 following a successful demonstration phase in 2017. Learn more about the key takeaways from multistakeholder consultation workshops.

Girls who are out of school or live in hard-to-reach communities can be missed by school-based HPV vaccination programs. Based on consultations in Burkina Faso, Ethiopia, Kenya, Lao People’s Democratic Republic, Malawi, and Nigeria, this executive summary highlights common challenges in identifying and enumerating these girls and practical approaches to strengthen data systems, community engagement, and planning. Explore the cross-country findings and related country briefs to learn more.

In this webinar, researchers from Burkina Faso and Mozambique shared learnings on how country-tailored interventions have helped increase the uptake of the malaria vaccine.As part of Gavi’s Malaria Vaccine Learning Agenda, experts presented findings and lessons learned from the rollout of malaria vaccines in Mozambique and Burkina Faso, sharing strategies to increase uptake through routine immunization platforms. This was the first in a quarterly series this year on learnings from malaria vaccine rollout in Africa.The session was co-moderated by Eleonora Genovese, Senior Programme Manager, Vaccine Programmes, Gavi, the Vaccine Alliance, and Saira Nawaz, Project Director, Primary Health Care, PATH. Featured speakers included Dr. Ali Sie, Centre de Recherche en Santé de Nouna (CRSN), Burkina Faso, and Daan Velthausz, Director, Maraxis BV, Mozambique.

Health systems require the right supplies and equipment to keep oxygen flowing. Supported by the Oxygen Delivery Gap Fund, PATH helped turn oxygen availability into respiratory care access across six African countries.

PATH conducted a study on behalf of the HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium on reaching out-of-school (OOS) girls with human papillomavirus (HPV) vaccination in low- and middle-income countries (LMICs). OOS girls are frequently missed by HPV vaccination campaigns where vaccine delivery is often centered around schools. PATH conducted interviews with 77 stakeholders in Bangladesh, Burkina Faso, Ethiopia, The Gambia, Mali, Senegal, and Solomon Islands to identify innovative strategies, challenges, and opportunities to vaccinate OOS girls against HPV. This brief provides a succinct summary of the study, high-level results, and key takeaways.

PATH conducted a study on behalf of the HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium on reaching out-of-school (OOS) girls with human papillomavirus (HPV) vaccination in low- and middle-income countries (LMICs). OOS girls are frequently missed by HPV vaccination campaigns where vaccine delivery is often centered around schools. PATH conducted interviews with 77 stakeholders in Bangladesh, Burkina Faso, Ethiopia, The Gambia, Mali, Senegal, and Solomon Islands to identify innovative strategies, challenges, and opportunities to vaccinate OOS girls against HPV. This slide deck provides a comprehensive overview of the study, including methods, key results and learnings, and recommendations for LMICs.

The Digital Health Applied Leadership Program (DHALP) is building a new generation of leaders equipped to champion digital transformation in ways that are sustainable, inclusive, and nationally owned.

The World Health Organization-recommended single-dose schedule for human papillomavirus (HPV) vaccination is expected to bring operational efficiencies and lower costs to country immunization programs. PATH conducted a study on behalf of the HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium to obtain insights into how switching to a single-dose schedule has impacted HPV vaccination programs in low- and middle-income countries and to gather insights for ongoing program planning and sustainability with a single-dose schedule. PATH conducted 35 semi-structured key informant interviews with national and subnational stakeholders in Burkina Faso, Ethiopia, and Solomon Islands to explore the operational aspects of switching from a two-dose to a one-dose HPV vaccination schedule across key thematic areas of the immunization program. This report shares high-level results from the study.

Piloted in 2021, the Digital Health Applied Leadership program (DHALP) is an executive training program that enhances participants’ capacity to successfully lead and execute digital health programs. With support from the United States Agency for International Development (USAID), the US President’s Emergency Plan for AIDS Relief (PEPFAR), BACKUP Health, and partners like the World Health Organization (WHO), the World Bank, and TechChange, the pilot program trained 42 leaders from four countries in planning digital health systems, management, and leadership. In an evaluation, participants indicated the relevance and practicality of training, increase in knowledge, confidence, application of concepts, and institutionalization of learning within the ministry. The program is currently (2025) being implemented in Burkina Faso, Rwanda, and Zambia with 60 midlevel digital health leaders.

Burkina Faso introduced typhoid conjugate vaccines (TCVs), becoming the first in Francophone Africa to include TCVs in the routine childhood immunization schedule.